Matching-adjusted comparison of the effectiveness and safety of Ensitrelvir versus Remdesivir for high-risk, hospitalized patients with non-severe COVID-19 in Japan
- 13 June 2026
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (8) , 103009
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19Infectious Diseases and Therapy, 2024
- Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease InhibitorInfectious Diseases and Therapy, 2024
- Ensitrelvir in patients with SARS-CoV-2: A retrospective chart reviewJournal of Infection and Chemotherapy, 2024
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19JAMA Network Open, 2024
- Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese AdultsClinical Drug Investigation, 2023
- Evaluation of Waning of SARS-CoV-2 Vaccine–Induced ImmunityJAMA Network Open, 2023
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialThe Lancet, 2022
- Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe DiseaseJAMA Network Open, 2022
- What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor designMedicinal Research Reviews, 2021
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020